Hanmi Science Co Ltd
KRX:008930

Watchlist Manager
Hanmi Science Co Ltd Logo
Hanmi Science Co Ltd
KRX:008930
Watchlist
Price: 29 050 KRW -0.34% Market Closed
Market Cap: 2T KRW
Have any thoughts about
Hanmi Science Co Ltd?
Write Note

Hanmi Science Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hanmi Science Co Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Hanmi Science Co Ltd
KRX:008930
Income from Continuing Operations
â‚©103.3B
CAGR 3-Years
24%
CAGR 5-Years
44%
CAGR 10-Years
16%
Yuhan Corp
KRX:000100
Income from Continuing Operations
â‚©162.4B
CAGR 3-Years
12%
CAGR 5-Years
30%
CAGR 10-Years
5%
SK Biopharmaceuticals Co Ltd
KRX:326030
Income from Continuing Operations
-â‚©35.4B
CAGR 3-Years
48%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Income from Continuing Operations
â‚©181.6B
CAGR 3-Years
26%
CAGR 5-Years
34%
CAGR 10-Years
16%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Income from Continuing Operations
â‚©10.8B
CAGR 3-Years
167%
CAGR 5-Years
-11%
CAGR 10-Years
-1%
C
Celltrion Pharm Inc
KOSDAQ:068760
Income from Continuing Operations
â‚©16.5B
CAGR 3-Years
-26%
CAGR 5-Years
81%
CAGR 10-Years
16%
No Stocks Found

Hanmi Science Co Ltd
Glance View

Market Cap
2T KRW
Industry
Pharmaceuticals

Hanmi Science Co Ltd, rooted in the vibrant economic landscape of South Korea, charts a compelling narrative of innovation and strategic positioning in the pharmaceutical industry. This company, established in the mid-1960s, has evolved into a pivotal player by capitalizing on its robust research and development initiatives. It operates primarily through its subsidiary, Hanmi Pharmaceutical, leveraging cutting-edge biotechnology to engineer novel drug formulations. Their core business model rests on leveraging proprietary technologies to transition new chemical entities from the lab to the market, focusing on niche therapeutic areas such as oncology, diabetes, and autoimmune diseases. By pursuing an aggressive patent strategy, Hanmi Science not only underscores its commitment to innovation but also fortifies its revenue streams by licensing these patented technologies to global pharmaceutical heavyweights. Revenue generation for Hanmi Science is intrinsically tied to its capacity to scale its biotech advances. The company's income flows primarily from licensing agreements, where its patented drug technologies are adopted by international partners, bringing in a steady stream of licensing fees and milestone payments. Additionally, Hanmi selectively engages in product distribution across multiple international markets, further diversifying its revenue base. This strategic mix of monetary inflow via direct product sales and licensing agreements allows Hanmi Science to reinvest substantial portions back into research and development, fueling a cycle of continuous innovation and market competitiveness. Through this dynamic model, Hanmi Science dexterously navigates the complexities of the pharmaceutical landscape, cementing its status as an innovator and a reliable partner in global health advancements.

Intrinsic Value
26 451.35 KRW
Overvaluation 9%
Intrinsic Value
Price

See Also

What is Hanmi Science Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
103.3B KRW

Based on the financial report for Sep 30, 2024, Hanmi Science Co Ltd's Income from Continuing Operations amounts to 103.3B KRW.

What is Hanmi Science Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
16%

Over the last year, the Income from Continuing Operations growth was 0%. The average annual Income from Continuing Operations growth rates for Hanmi Science Co Ltd have been 24% over the past three years , 44% over the past five years , and 16% over the past ten years .

Back to Top